Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Status
Active
Cancer Type
Acute Lymphoblastic Leukemia
Trial Phase
Phase II
Eligibility
1 to 21, Male and Female
Study Type
Treatment
NCT ID
NCT02723994
Protocol IDs
INCB 18424-269 (primary)
NCI-2016-01687
AALL1521
Study Sponsor
Incyte Corporation

Summary

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the

study will optimize the dose of study drug (ruxolitinib) in combination with the

chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and

ruxolitinib at the recommended dose determined in Part 1.

Treatment Sites in Georgia

Aflac Cancer and Blood Disorders Center of Children’s at Egleston


1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322
404-785-0853
www.choa.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.